13 septembre 2023
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.841.1647
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37702466
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7E99572678E46
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2025-03-13 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
A. Damianaki et al., « Hyperkaliémie chez le patient hypertendu : plus qu’une coïncidence ? [Hyperkaliemia in hypertensive patients : more than a coincidence?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.841.1647
Hyperkaliemia is a relatively common electrolyte disorder whose manifestations and consequences can be serious if severe hyperkalemia is not treated. In the context of hypertension, it is important to look for co-morbidities and conditions favoring hyperkaliemia, to review the drugs prescribed that could contribute to potassium elevation and to bear in mind that when the common causes have been excluded, a genetic origin may be present. In this article, the focus is on the association of hypertension and hyperkaliemia, in the context of the marketing of new cardiovascular and renal drugs that may induce this electrolyte disorder.